Literature DB >> 34341353

SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation.

Pan Pan1,2, Miaomiao Shen3, Zhenyang Yu3, Weiwei Ge3, Keli Chen3, Mingfu Tian2,3, Feng Xiao3, Zhenwei Wang2, Jun Wang4, Yaling Jia2, Wenbiao Wang2, Pin Wan2, Jing Zhang2, Weijie Chen2, Zhiwei Lei2, Xin Chen2, Zhen Luo2,5, Qiwei Zhang2,5, Meng Xu1, Geng Li6,7, Yongkui Li8,9, Jianguo Wu10,11,12,13.   

Abstract

Excessive inflammatory responses induced upon SARS-CoV-2 infection are associated with severe symptoms of COVID-19. Inflammasomes activated in response to SARS-CoV-2 infection are also associated with COVID-19 severity. Here, we show a distinct mechanism by which SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce hyperinflammation. N protein facilitates maturation of proinflammatory cytokines and induces proinflammatory responses in cultured cells and mice. Mechanistically, N protein interacts directly with NLRP3 protein, promotes the binding of NLRP3 with ASC, and facilitates NLRP3 inflammasome assembly. More importantly, N protein aggravates lung injury, accelerates death in sepsis and acute inflammation mouse models, and promotes IL-1β and IL-6 activation in mice. Notably, N-induced lung injury and cytokine production are blocked by MCC950 (a specific inhibitor of NLRP3) and Ac-YVAD-cmk (an inhibitor of caspase-1). Therefore, this study reveals a distinct mechanism by which SARS-CoV-2 N protein promotes NLRP3 inflammasome activation and induces excessive inflammatory responses.
© 2021. The Author(s).

Entities:  

Year:  2021        PMID: 34341353     DOI: 10.1038/s41467-021-25015-6

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  82 in total

Review 1.  NLRP3 inflammasome activation and SARS-CoV-2-mediated hyperinflammation, cytokine storm and neurological syndromes.

Authors:  Debashis Dutta; Jianuo Liu; Huangui Xiong
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2022-06-15

Review 2.  The Disease-Modifying Role of Taurine and Its Therapeutic Potential in Coronavirus Disease 2019 (COVID-19).

Authors:  Larissa E van Eijk; Annette K Offringa; Maria-Elena Bernal; Arno R Bourgonje; Harry van Goor; Jan-Luuk Hillebrands
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

Review 3.  Therapeutic Targeting of Innate Immune Receptors Against SARS-CoV-2 Infection.

Authors:  Mariya Farooq; Abdul Waheed Khan; Bilal Ahmad; Moon Suk Kim; Sangdun Choi
Journal:  Front Pharmacol       Date:  2022-06-30       Impact factor: 5.988

4.  Circulatory Exosomes from COVID-19 Patients Trigger NLRP3 Inflammasome in Endothelial Cells.

Authors:  Subhayan Sur; Robert Steele; T Scott Isbell; Ranjit Ray; Ratna B Ray
Journal:  mBio       Date:  2022-05-19       Impact factor: 7.786

Review 5.  Adipose Tissue Inflammation and Pulmonary Dysfunction in Obesity.

Authors:  Giuseppe Palma; Gian Pio Sorice; Valentina Annamaria Genchi; Fiorella Giordano; Cristina Caccioppoli; Rossella D'Oria; Nicola Marrano; Giuseppina Biondi; Francesco Giorgino; Sebastio Perrini
Journal:  Int J Mol Sci       Date:  2022-07-01       Impact factor: 6.208

Review 6.  Inflammasome activation: from molecular mechanisms to autoinflammation.

Authors:  Samuel Lara-Reyna; Emily A Caseley; Joanne Topping; François Rodrigues; Jorge Jimenez Macias; Sean E Lawler; Michael F McDermott
Journal:  Clin Transl Immunology       Date:  2022-07-07

Review 7.  Mechanisms of Immune Dysregulation in COVID-19 Are Different From SARS and MERS: A Perspective in Context of Kawasaki Disease and MIS-C.

Authors:  Manpreet Dhaliwal; Rahul Tyagi; Pooja Malhotra; Prabal Barman; Sathish Kumar Loganathan; Jyoti Sharma; Kaushal Sharma; Sanjib Mondal; Amit Rawat; Surjit Singh
Journal:  Front Pediatr       Date:  2022-05-05       Impact factor: 3.569

Review 8.  Pathogenic Mechanism and Multi-omics Analysis of Oral Manifestations in COVID-19.

Authors:  Ming Hao; Dongxu Wang; Qianyun Xia; Shaoning Kan; Lu Chang; Huimin Liu; Zhijing Yang; Weiwei Liu
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

9.  The Remarkable Selectivity of Nirmatrelvir.

Authors:  Damien Y Duveau; Craig J Thomas
Journal:  ACS Pharmacol Transl Sci       Date:  2022-05-17

10.  Inflammasome activation in infected macrophages drives COVID-19 pathology.

Authors:  Esen Sefik; Rihao Qu; Caroline Junqueira; Eleanna Kaffe; Haris Mirza; Jun Zhao; J Richard Brewer; Ailin Han; Holly R Steach; Benjamin Israelow; Holly N Blackburn; Sofia E Velazquez; Y Grace Chen; Stephanie Halene; Akiko Iwasaki; Eric Meffre; Michel Nussenzweig; Judy Lieberman; Craig B Wilen; Yuval Kluger; Richard A Flavell
Journal:  Nature       Date:  2022-04-28       Impact factor: 69.504

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.